Using a Whole-Person Approach in Supportive Care to Improve Cancer Outcomes

Commentary
Video

The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.

Andrew T. Leitner, MD, spoke with CancerNetwork® regarding the Together for Supportive Cancer Care coalition and how it was designed to take a whole-person care approach that is often missed throughout different treatment strategies.

Leitner, chair in the Department of Supportive Care Medicine, associate clinical professor in the Department of Anesthesiology, and chief in the Division of Interventional Patin Management at City of Hope in Duarte, California, also highlighted that the coalition aims to advance the national conversation surrounding supportive cancer care to impact key factors such as health care utilization and cost-effectiveness of therapy. Emphasizing the possibility of accomplishing “more together,” Leitner expressed his hope in having other partners join the coalition to bring in more focused philanthropic support.

Formed based on the recognition of the insufficiency of current supportive care services, the coalition aims to improve the overall patient experience. Additionally, the coalition aims to share best practices for patients and caregivers to help with the supportive care environment.

Transcript:

What we’re looking to do is advance the comprehensive, whole-person approach to cancer care that we know supportive care provides. This kind of coalition work is greater than the sum of its parts that are limited either to geographies, resource constraints, or smaller constituencies. By coming together to advance the national conversation, we can move some of the metrics by which we are able to provide these services, whether it’s in the payer landscape or recognition of how closely these are tied to outcomes, including health care utilization and cost-effectiveness. We do more together, and this coalition is an example of where we can bring in focused philanthropic support. For that, we have the Biller Family Foundation to thank for bringing us together in this type of forum, as well as increasing buy-in from partner organizations to move this forward. We hope others will join us.

Recent Videos
Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.
BCMA testing tracks clinical changes faster without the need for marker expression vs monoclonal immunoglobulin, a conventional multiple myeloma marker.
Studies indicate that higher BCMA levels are associated with a greater need for therapy years following diagnosis for patients with smoldering myeloma.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.